Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$221.42 - $260.97 $794,454 - $936,360
-3,588 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $635,111 - $801,738
3,588 New
3,588 $788,000
Q2 2021

Aug 16, 2021

SELL
$187.49 - $221.1 $811,456 - $956,920
-4,328 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$207.02 - $241.31 $109,306 - $127,411
528 Added 13.89%
4,328 $931,000
Q4 2020

Feb 12, 2021

BUY
$207.01 - $276.09 $157,948 - $210,656
763 Added 25.12%
3,800 $898,000
Q3 2020

Nov 13, 2020

BUY
$255.65 - $303.1 $583,648 - $691,977
2,283 Added 302.79%
3,037 $830,000
Q2 2020

Aug 14, 2020

SELL
$225.48 - $295.8 $145,660 - $191,086
-646 Reduced 46.14%
754 $219,000
Q1 2020

May 15, 2020

BUY
$199.77 - $247.81 $279,678 - $346,934
1,400 New
1,400 $333,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Maven Securities LTD Portfolio

Follow Maven Securities LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Maven Securities LTD, based on Form 13F filings with the SEC.

News

Stay updated on Maven Securities LTD with notifications on news.